Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock: Insider Renee Gala Sells 1,000 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 1,000 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total value of $225,370.00. Following the completion of the sale, the chief executive officer owned 140,394 shares in the company, valued at approximately $31,640,595.78. This represents a 0.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Down 3.1%

Shares of Jazz Pharmaceuticals stock traded down $7.34 during trading hours on Thursday, hitting $227.32. The company had a trading volume of 670,555 shares, compared to its average volume of 933,464. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.58. The company’s 50-day moving average is $230.15 and its two-hundred day moving average is $217.11. The company has a market cap of $14.59 billion, a P/E ratio of 77.32, a price-to-earnings-growth ratio of 0.46 and a beta of 0.38. Jazz Pharmaceuticals PLC has a twelve month low of $128.80 and a twelve month high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the previous year, the company posted $8.13 EPS. The company’s quarterly revenue was up 10.4% on a year-over-year basis. Analysts anticipate that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current fiscal year.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported third-quarter revenue of $1.24 billion, above expectations of $1.21 billion, and EPS that also beat consensus. Revenue rose 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Earnings coverage
• Positive Sentiment: Analyst sentiment was supportive after the results: RBC and Morgan Stanley reportedly saw further upside, while Barclays and JPMorgan raised their price targets. RBC analyst outlook Barclays price target Morgan Stanley outlook JPMorgan price target
• Neutral Sentiment: Director Bruce Cozadd sold 6,000 shares for about $1.30 million under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by 1.73%, but he retained 339,875 shares. Director sale details

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. USA Financial Formulas acquired a new stake in Jazz Pharmaceuticals during the first quarter worth about $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth about $32,000. Ameritas Advisory Services LLC acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $47,000. Westpac Banking Corp acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $51,000. Finally, Root Financial Partners LLC lifted its stake in shares of Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after purchasing an additional 89 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Barclays upped their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday. Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Wall Street Zen downgraded Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 3rd. Piper Sandler upped their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Morgan Stanley raised their price target on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an “overweight” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $293.45.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.